Germany· DE-A57-12f4026f84c3f24d
Olmetec Plus
A medicinal product containing olmesartan medoxomil, hydrochlorothiazide, registered in Germany by Daiichi Sankyo Europe Gmbh.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Olmesartan Medoxomil, Hydrochlorothiazide
- Manufacturer
- Daiichi Sankyo Europe Gmbh
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Olmesartan medoxomil, hydrochlorothiazide in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBenicar HCTCosette Pharmaceuticals, Inc.
- ItalyIDALAZIDEISTITUTO BIOCHIMICO NAZIONALE SAVIO S.R.L.
- CzechiaSARTEN PLUS HMenarini International Operations Luxembourg S.A., Luxembourg
- CanadaACH-OLMESARTAN HCTZACCORD HEALTHCARE INC
- FinlandBenetor CompMenarini International Operations Luxembourg S.A.
- IrelandOlmesartan/Hydrochlorothiazide Clonmel 20 mg/12.5 mg film-coated tabletsClonmel Healthcare Ltd
- FranceALTEISDUO 20 mg/12,5 mg, comprimé pelliculéMENARINI INTERNATIONAL OPERATIONS LUXEMBOURG
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Mencord Plus, Olmeblo Hct
- Belgium · Belsar Plus, Co-Olmesartan
- Bulgaria · Olmesartan/Hctz Mylan, Ко-Олиместра
- Cyprus · Olartan-Plus, Olmesartan/Hydrochlorothiazide Tad
- Czechia · Sarten Plus H, Zeota Hct
- Denmark · Olmesartan Medoxomil/Hydrochlorothiazide Krka
- Estonia · Co-Olimestra, Mesar Plus
- Spain · Atolme Plus, Ixia Plus
- Finland · Olmesartan Medoxomil/Hydrochlorothiazide Krka
- France · Alteisduo, Coolmetec
- United Kingdom (Northern Ireland) · Olmesartan Medoxomil/Hydrochlorothiazide Accord Healthcare, Olmesartan Medoxomil/Hydrochlorothiazide Msn Laboratories Europe
- Greece · Co-Ipertas, Olartan-Plus
- Croatia · Co-Olimestra, Olmesartan/Hidroklorotiazid Genericon
- Hungary · Laresin Plus
- Ireland · Olmesartan/Hydrochlorothiazide Clonmel, Olmesartan/Hydrochlorothiazide Krka
- Italy · Idalazide, Olmegan
- Lithuania · Co-Olimestra, Mesar Plus
- Luxembourg · Belsar Plus, Olmesartan Plus Hct
- Latvia · Co-Olimestra, Mesar Plus
- Malta · Olmesartan Medoxomil/Hydrochlorothiazide Msn, Olmesartan/ Hydrochlorothiazide Msn
- Netherlands · Hydrochlorothiazide/ Olmesartan Medoxomil Aurobindo, Hydrochlorothiazide/Olmesartan Medoxomil Aurobindo
- Norway · Olmesartan Medoxomil/Hydrochlorothiazide Krka
- Poland · Co-Olimestra, Osaver Hct
- Portugal · Olmesartan + Hidroclorotiazida Sandoz, Olmesartan Medoxomilo + Hidroclorotiazida Alter
- Slovenia · Co-Tensiol, Olmicombi
- Slovakia · Tenzar Plus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da93637f-7efd-415c-9a56-edebe1f3de26 GET /v1/drugs/da93637f-7efd-415c-9a56-edebe1f3de26?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Olmesartan Medoxomil, Hydrochlorothiazide",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about olmesartan medoxomil, hydrochlorothiazide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.